Pembrolizumab (Keytruda)

This drug is an immune checkpoint inhibitor that targets PD-1, a protein on immune system cells (called T cells), that normally help keep these cells from attacking other cells in the body. By blocking PD-1, this drug boosts the immune response against melanoma cells. This can often shrink tumours and help people live longer. Keytruda is normally given as an intravenous (IV) infusion every 3 weeks to 6 weeks. 

Side Effects

The most common side effects from this drug include fatigue, diarrhea, skin rash, and itching. Serious side effects seem to happen more often with this drug than with the PD-1 inhibitors. Like the PD-1 inhibitors, this drug can cause the immune system to attack other parts of the body, which can lead to serious problems in the intestines, liver, hormone-making glands, nerves, skin, eyes, or other organs. In some people these side effects have been fatal. 

It’s very important to report any new side effects during or after treatment to your health care team promptly. 

Watch Now – Video on the side effects of Immunotherapies

Provincial Funding Summary

View Summary PDF

Ipilimumab (Yervoy) for Advanced Melanoma
This information is current as of August 4, 2016

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

View the Provincial Funding Summary through CADTH Pan-Canadian Oncology Drug Review Click here